Prevail InfoWorks

This inspiring article from Pfizer follows a patient named Eric through his clinical trial journey. For those looking to learn more about the clinical trial process, this is a great resource. “From the thousands of patients who volunteer each year to the scientists, clinicians, and principal investigators (PIs), each individual who contributes to a trial helps to bring about life-changing treatments and advances our knowledge of diseases.” #ClinicalTrials #Patients #Safety #Discovery https://lnkd.in/eUQEb2bn

You are no doubt on the lookout for resources that will bring you wide-ranging success. Could the winning formula be you and Prevail InfoWorks as an?Functional Service Provider (FSP)?—from site identification to post-database lock statistical programming??Also the complete systems suite including The Single Interface??is exhibiting at CRO COGS?(Clinical Outsourcing Group Summit)?in Raleigh, North Carolina on December 3-4.?Join the conversation at Booth 19 to know how you can start collecting your earned-value, faster! PBC Group - Organisers of the COG Series #CROCOGS #ClinicalTrials #ClinicalResearchandDevelopment #CROInnovation #PrevailInfoWorks #LifeSciencesSolutions

Boston, That’s a Wrap! Prevail InfoWorks’ Success at the PCTO Summit The visitors during the Precision in Clinical Trials Oncology (PCTO) Summit Boston conference had an exceptional time with us at our booth and during the highest rated talk of the conference. Lots of people left the talk and made a bee line to the Prevail exhibit of live studies using an integrated analytics approach. The award for the?Most Enthusiastic Exhibit Visitor?goes to Alissa R., a biotech's Director and Clinical Project Manager who challenged Prevail to show her the integration of Safety, IRT, Labs, EDC and a whole set of different vendors for their historical phase 2 that have been unintegrated before now. Raleigh, North Carolina is next up! Starting Monday, December 3rd-4th, we will be at the COG (Clinical Outsourcing Group) CRO Summit, which brings together leaders from Clinical Research Organizations and Functional Service Providers (FSP). #PrevailInfoWorks #CRO #ClinicalResearchOrganization #FSP #FunctionalServiceProvider #PCTOncologySummit #OncologyClinicalTrials #Oncology #ClinicalData #DataIntegration #ClinicalAnalytics #PrecisionInClinicalTrials #Boston #LifeSciencesNetworking #IndustryLeaders #InnovatorsInOncology #HealthcareInnovation #OncologyResearch #FutureOfMedicine?

Halozyme’s Bold €2 Billion Bid: A Game-Changer in Drug Delivery? Halozyme, Inc. makes a significant and exciting bid to acquire Evotec after interest from other investors was sparked. Halozyme sees a potential opportunity to combine their ENHANZE drug delivery technology with Evotech’s own drug delivery capabilities to help diversify their revenue streams. Here are some more exciting details on this potential deal: -Acquisition Offer: Halozyme Therapeutics bid €2 billion ($2.1 billion) to acquire Evotec, offering a 27.5% premium over Evotec's last closing price. Evotec is analyzing the proposal. -Strategic Fit: Halozyme aims to diversify and extend its revenue streams, leveraging Evotec's drug discovery platform and manufacturing capabilities to complement its ENHANZE technology. -Competitive Interest: The bid follows interest from Triton Partners, which recently acquired nearly 10% of Evotec. Evotec's stock surged 20% following the news, trading just below Halozyme's offer. -Long-Term Strategy: Halozyme plans to sustain revenue beyond ENHANZE’s patent expiry (2027) through royalties and acquisitions like Evotec, building on prior moves like the 2022 purchase of Antares Pharma for $960M. What are your thoughts on Halozyme’s strategy with this potential acquisition? Will we see other investors step up to the plate after this huge bid? Buying Evotec would “diversify and extend Halozyme revenue and EBITDA growth and durability well into the next decade and beyond,” says Helen Torley, Halozyme’s CEO. Halozyme also stated that Evotec’s drug discovery platform would serve as a key center of excellence, while its manufacturing capabilities would enhance the functionality of ENHANZE. #PharmaInnovation #BiotechMergers #StrategicAcquisition #DrugDeliveryTechnology #PharmaGrowth #BiotechNews #HalozymeTherapeutics #Evotec #Acquisition #BiotechStrategy #PharmaInvestments #DrugDiscovery #MergersAndAcquisitions #LifeSciences #HealthcareInnovation #IndustryInsights

Hello, Boston! We're here and ready to connect Exciting things are happening as Prevail InfoWorks at Booth 6 dives into Precision in Clinical Trials Oncology (PCTO) Summit Boston hosted by Precision Evolution Global. From meeting incredible minds to discovering the latest in the future of oncology trials, innovative approaches to patient care, and cutting-edge technology shaping the field. You’re in for an amazing experience. In oncology, precision and reliability are key to advancing clinical research. Prevail InfoWorks supports oncology companies with a full range of specialized clinical trial services and advanced technologies, designed to enhance every aspect of the trial process—from streamlined operations to superior data accuracy. If you’re at the summit, come by Booth 6 for an interactive experience. We're here to learn, connect, share, and explore new partnerships. Let’s make oncology trials more precise, efficient, and impactful together. #Networking #IndustryInnovation #Collaboration #MakingConnections #ExcitingTimes #PCTOSummit #Oncology #Summit??

Hope on the Horizon: New Huntington’s Disease Therapies Near the Finish Line After four challenging years for the Huntington’s community, optimism is rising as companies like Prilenia and Wave Life Sciences pursue approval for therapies that may target the disease's root cause. Three decades after identifying the huntingtin gene—and numerous setbacks later—a fresh wave of Huntington's disease therapies is approaching the final stages of development, each striving to become the first treatment to modify the course of this challenging and fatal condition. Here are some more exciting details: -Renewed Hope: Companies like Prilenia and Wave are pushing Huntington’s therapies closer to approval. -Promising Trials: Key drugs, including pridopidine and WVE-003, show encouraging trial results. -New Targets: Innovative approaches focus on gene and protein modifications to slow disease progression. -Careful Progress: Experts support accelerated approval but stress the need for safety. With increasing optimism as developments progress, how might these potential treatments change the lives of those affected by Huntington’s disease? What do you think are the biggest challenges remaining for Huntington’s therapies to reach final approval? Commenting on the safety and future of these new drugs, “We need to make sure that these therapies are really safe if we don’t want to be in a situation like some of the Alzheimer’s drugs where there’s a lot of reported side effects, including deaths that [were] maybe worse . . . than what the trials actually initially reported,” says Ignacio Munoz-Sanjuan, chairman of Rumi Scientific and president of the Huntington’s-focused non-profit Factor-H HD. Feel free to read more about this in the article linked below. #HuntingtonsDisease #GeneTherapy #NeurodegenerativeDiseases #MedicalInnovation #DrugDevelopment #ClinicalTrials #HopeForHuntingtons #HealthcareAdvances #Therapeutics #Biotechnology #PatientSafety #BreakthroughsInMedicine #GeneticResearch #RareDisease #Prilenia #WaveLifeSciences

Biogen Enters the Molecular Glue Race—Will This Be the Key to Tackling Neurological Diseases? Biogen is the latest major player in biotech to invest in protein degradation, announcing a deal to leverage Neomorph, Inc.’s molecular glue degrader discovery platform. The two companies will jointly create targeted small-molecule glue degraders, with Biogen leading successful candidates through clinical trials and toward commercialization. Here are some details on this exciting deal: -Biogen-Neomorph Deal: Biogen partners with Neomorph to target Alzheimer’s, rare neurological, and immunological diseases, leveraging Neomorph's molecular glue technology. -Funding: Neomorph will receive an upfront payment, up to $1.45 billion in milestone payments, research cost reimbursements, and future royalties. -Focus on Molecular Glue Degraders: The collaboration aims to create small molecule degraders that can tag proteins for destruction, addressing previously "undruggable" targets. Industry Trend: Biogen joins major companies like Novartis, Pfizer, and Eisai US, who also recently invested in molecular glue technologies. As this area gains more and more attention from big companies, could molecular glue technologies be the breakthrough biotech needs to unlock treatments for complex neurological and immunological diseases? "As part of our modality agnostic research strategy, Biogen is committed to investing in new approaches to unlock biological targets that have remained difficult to reach," says Biogen research head Jane Grogan, Ph.D. Feel free to check out the article linked below. #BiotechInnovation #MolecularGlue #ProteinDegradation #TargetedTherapies #NeurologicalDiseases #AlzheimersResearch #Biogen #Neomorph #DrugDiscovery #Immunology #UndruggableTargets #ClinicalTrials #BiotechPartnerships #NextGenTherapies #MedicalBreakthroughs #BiotechTrends

Roche’s Trontinemab Takes Aim at Accelerated Approval for Alzheimer’s – Is Speedy Access on the Horizon? In an exciting move, Roche may seek an accelerated U.S. FDA approval for its latest Alzheimer’s drug, trontinemab, if Phase 3 trial results continue to show a significant reduction in amyloid, a key protein associated with cognitive decline. Here are the key takeaways of the article: -Potential Game-Changer in Amyloid Reduction: Early Phase 2 data suggests trontinemab may reduce amyloid faster than Eli Lilly and Company's Kisunla, with more than half of the high-dose group showing cleared amyloid after 28 weeks.? -Crossing the Blood-Brain Barrier: Trontinemab is designed to cross the blood-brain barrier more easily, potentially delivering stronger effects at a lower dose.? -Enhanced Safety Profile: Roche's trial data shows trontinemab led to lower rates of ARIA (brain swelling indicator) compared to Kisunla and Leqembi. So far, less than 10% of trontinemab patients experienced ARIA, while Kisunla's rate was over 20%.? -Streamlined, Patient-Friendly Dosing: Roche aims to implement a low-frequency maintenance dose to prevent amyloid rebound, offering patients a more convenient treatment option.? -Safety Adjustments: Roche updated its enrollment criteria after one volunteer experienced brain bleeding, reducing risk for future participants. Could trontinemab’s accelerated approval path lead to faster access for Alzheimer’s patients? Share your thoughts in the comment below. Read more in the comment section. #AlzheimersTreatment #NeurologyInnovation #HealthcareAdvances #FDAApproval #AcceleratedApproval #AmyloidReduction #RochePharma #BrainHealth #ClinicalResearch #FutureOfMedicine?

No tricks, just treats at Prevail InfoWorks Did you know Halloween’s origins trace back to the ancient Celtic festival of Samhain, where people lit bonfires and wore costumes to ward off ghosts? This Halloween, we’re scaring away clinical trial challenges with our cutting-edge technologies and spook-tacular services. From taming data monsters to vanquishing oversight nightmares, our patented processes ensure every trial has the best chance for success.? Don’t let your trial get haunted by inefficiencies! With our exceptional clinical trial support, you’ll achieve frighteningly good outcomes every step of the way. Let’s treat your trial to smoother processes, sharper data quality, and a successful journey! #PrevailInfoWorks #HalloweenFun #ClinicalTrials #LifeSciences #DataQuality #ClinicalResearch #Oversight #Innovation #PatentedProcess #TechnologyDriven #HappyHalloween

AbbVie Expands Its Alzheimer’s Arsenal: Insights from the $1.4B Aliada Deal AbbVie is acquiring Aliada Therapeutics for $1.4 billion, securing the Alzheimer’s candidate ALIA-1758, which features a specialized mechanism to cross the blood-brain barrier and boost brain uptake. This acquisition also provides AbbVie with Aliada’s versatile delivery platform, expanding opportunities for neurological treatments. Here are some key insights on this exciting deal: -AbbVie Acquisition: AbbVie is buying Aliada Therapeutics for $1.4 billion to secure an innovative Alzheimer’s drug, ALIA-1758. -Drug Advantage: ALIA-1758 uniquely targets pyroglutamate amyloid beta and crosses the blood-brain barrier for better brain uptake. -Strategic Shift: AbbVie dropped its own Alzheimer’s candidate, betting on ALIA-1758 as a more differentiated option. -Broader Potential: AbbVie gains Aliada’s BBB (blood-brain barrier) delivery platform, enhancing potential treatments for other neurological conditions. How could AbbVie’s acquisition of ALIA-1758 and BBB-penetrating technology reshape the future of Alzheimer's and neurological treatments? Will we see a more competitive landscape after this huge deal? Feel free to learn and read more about this in the article linked below. #AbbVie #AliadaTherapeutics #Alzheimers #Neuroscience #Pharmaceuticals #DrugDevelopment #Innovation #Biotechnology #BloodBrainBarrier #NeurologicalHealth #HealthcareInvestment #PharmaNews #ResearchAndDevelopment #Biopharma #TargetedTherapy #ClinicalTrials #MedicalBreakthroughs #LifeSciences #MentalHealth #HealthcareInnovation